TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17523385
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) with Betulaceae extracts
Study: 30589965
Drug: Vonoprazan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (20 mg daily)
Study: 28680717
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg daily)
Study: 25773009
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose multivitamin and mineral supplement (1× RDI for 30 days, then 2× RDI for 30 days)
Study: 23447043
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of indapamide
Study: 23447043
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of indapamide
Study: 20872082
Drug: Adverse Drug
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse Drug Events (ADEs)
Study: 20872082
Drug: Medication Errors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Errors
Study: 19576324
Drug: ERN/LRPT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT (1 g for 4 weeks advanced to 2 g for 12 weeks)
Study: 17054812
Drug: 6% HES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% HES 130/0.42 with balanced crystalloid solution (Group A)
Study: 17054812
Drug: Conventional HES
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HES 130/0.42 plus unbalanced crystalloid (saline solution) (Group B)
Study: 11838060
Drug: Implantation group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation group (20 patients) - implanted with compound artificial bone of HA‐Bone cement
Study: 9565283
Drug: Magnetized water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetized water oral irrigator
Study: 12589712
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concomitant chemotherapy
Study: 28625164
Drug: Weekly teleconsultations
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly teleconsultations with a specialist palliative care consultation team (SPCT) for 12 weeks
Study: 18753862
Drug: TPV/r 375/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 375/150 mg/m twice-daily
Study: 18753862
Drug: TPV/r (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r (both doses)
Study: 8678570
Drug: Itraconazole (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (7 mg/kg per day) for 3 weeks
Study: 23838692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (access to a range of interventions, but not multi-family therapy)
Study: 24133059
Drug: Garcinia cambogia
Normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia cambogia extract (2.4 g, 800 mg 3×/day, 50% HCA)
Study: 19070025
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ferrous sulfate 5 times/week
Study: 16335907
Drug: Metformin (MET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (MET group, n = 48)
Study: 11995344
Drug: PGE1 infusion
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (30‐40 hrs)
Study: 12854476
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PGE1 infusion)
Study: 9701620
Drug: Dietary vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary vitamin C intake (100 mg increment)
Study: 8904263
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (4 mg immediately after operation and 3 mg ten hours later)
Study: 8904263
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine premedication (0.14 mg/kg)
Study: 1898841
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drug groups
Study: 30152603
Drug: STEPPS +
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: STEPPS + treatment as usual
Study: 23724353
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/d
Study: 16316482
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/d
Study: 7702445
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg/d
Study: 9657442
Drug: Nadroparin administered
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin administered subcutaneously once daily at a dose of 180 anti-factor Xa IU.kg(‐1) for 6 to 10 days
Study: 2059591
Drug: Hydralazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (10 mg)
Study: 7295463
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg)
Study: 6955678
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline hydrochloride 100 mg bid for 10 days
Study: 31469508
Drug: Multidose drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose drug dispensing (MDD)
Study: 24801148
Drug: Ordinary prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary prescriptions (no MDD)
Study: 19647623
Drug: Preoperative glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative glutamine supplementation (0.3 g . kg(‐1) x d(‐1) for 5 days)
Study: 17721395
Drug: Raltegravir (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (100, 200, 400, and 600 mg twice daily)
Study: 17721395
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg/d)
Study: 9615306
Drug: Furosemide aerosol
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide aerosol (100 mg)
Study: 7856472
Drug: Nicardipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (1 mg/Kg/day)
Study: 2610509
Drug: Cefixime alone
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime alone (400 mg)
Study: 2610509
Drug: Cefixime simultaneous
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime simultaneous with antacid (Maalox; 20 ml)
Study: 22093203
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg daily
Study: 1361935
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg daily
Study: 3780161
Drug: Piperacillin 4
Normalized name: piperacillin 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin 4 g (sodium salt)
Study: 3780161
Drug: Azlocillin 4
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azlocillin 4 g (sodium salt)
Study: 22014477
Drug: Aggressive early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive early passive rehabilitation (manual therapy 2 times per day and unlimited self-passive stretching exercise) in group A (30 shoulders)
Study: 20399945
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg ethinylestradiol/2 mg chlormadinone acetate (EE/CMA)
Study: 20399945
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg ethinylestradiol/0.15 mg desogestrel (EE/DSG)
Study: 20399945
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg ethinylestradiol/0.15 mg levonorgestrel (EE/LNG)
Study: 1774421
Drug: L-deprenyl
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl
Study: 15884476
Drug: Cryotherapy (frozen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy (frozen gel band)
Study: 15884476
Drug: Cryotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy and Acetaminophen
Study: 2146634
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (1000 mu g)
Study: 363053
Drug: Netilmicin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (2 mg/kg, intramuscularly every 12 h for 7 to 10 days)
Study: 363053
Drug: Amikacin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (7.5 mg/kg, intramuscularly every 12 h for 7 to 10 days)
Study: 23958252
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 10 mg
Study: 21982664
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 40 mg
Study: 23958252
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 100 mg
Study: 14757293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rosiglitazone (8 mg per day) and glibenclamide (7.5 mg per day)
Study: 14757293
Drug: Glibenclamide monotherapy
Normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glibenclamide monotherapy (up-titration to maximum dose of 15 mg per day)
Study: 20518153
Drug: SSRI antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI antidepressant drugs (e.g., Prozac)
Study: 15389280
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG) 2 g/kg body weight over 2 days
Study: 11135227
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of dendritic cells (DCs).
Study: 3977334
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil solution
Study: 6239893
Drug: 0%, 1%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0%, 1%, 3% minoxidil solutions
Study: 29223722
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib (40 mg diluted in 2 mL, given 30 minutes before surgery and every 12 hours for 48 hours)
Study: 29223722
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 mL normal saline given at the same intervals)
Study: 26920599
Drug: Oral Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulation (OAC) monotherapy
Study: 26920599
Drug: OAC monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC monotherapy
Study: 29771270
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (Control)
Study: 11106134
Drug: Alprazolam SR
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam SR (1.5 mg)
Study: 11106134
Drug: Bromazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (3 mg taken three times daily)
Study: 11106134
Drug: Lorazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1 mg taken three times daily)
Study: 28844192
Drug: Rivaroxaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5 mg twice daily)
Study: 22963754
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine gel
Study: 12795748
Drug: Furazolidone 2
Normalized name: furazolidone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 2 x 50 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day
Study: 12795748
Drug: Furazolidone 2
Normalized name: furazolidone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 2 x 200 mg + amoxycillin 2 x 1 g + omeprazole 2 x 20 mg/day
Study: 10381910
Drug: rhIL‐11 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL‐11 40 microgram. kg‐1. wk‐1 (2 or 5 times weekly for 3 weeks)
Study: 1669669
Drug: Taurine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (30 mg/kg per day)
Study: 25945550
Drug: Placebo treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment; details not specified.
Study: 25945550
Drug: Transcranial bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial bright light (TBL) treatment; administered as intermittent light exposures (4 × 12 min) during the 7-day post-travel period after an eastward transatlantic flight.
Study: 15943939
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (4-24 mg)
Study: 15943939
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (20-100 mg)
Study: 19761076
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens
Study: 6789720
Drug: 2% cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% cromolyn solution
Study: 30971750
Drug: Untreated apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated apple juice (free glucose 8.5 g; bound glucose 6.7 g; gluconate below detection limit)
Study: 27718013
Drug: L-DOPA administration
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA administration
Study: 23565815
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g of omega-3 fatty acids (O3) per day for 4 weeks
Study: 17334533
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dosage: 13.6 +/- 6.9 mg)
Study: 17334533
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean dosage: 5.8 +/- 3.8 mg)
Study: 6369883
Drug: Bendroflumethiazide 2.5
Normalized name: bendroflumethiazide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 2.5 mg
Study: 15201559
Drug: Nifedipine LA
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine LA 30 mg
Study: 27004411
Drug: Isoflavone-enriched soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-enriched soy extract (117.4 mg/day isoflavone aglycone equivalents) for 12 weeks
Study: 23528159
Drug: V +
Normalized name: Black Catechu Wood/Chinese Skullcap/Chondroitin Sulfate Sodium/Dimethyl Sulfone/Glucosamine Hydrochloride/Hyaluronic Acid 66.667 MG-500 MG-500 MG-1.1 MG Oral Tablet [FOSTER&THRIVE GLUCOSAMINE CHONDROITIN ADV +MSM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: V + C (oral vinorelbine at 80 mg/m², then 60 mg/m² after first cycle, and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Study: 23528159
Drug: V↔C (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: V↔C (oral vinorelbine weekly and capecitabine at 1,000 mg/m² bid from days 1 to 14)
Study: 19952980
Drug: REPEVAX administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: REPEVAX administered concomitantly with GARDASIL
Study: 19952980
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of GARDASIL and REPEVAX
Study: 18584876
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with 4 mg triamcinolone acetonide (TA) injected into the silicone-filled vitreous cavity
Study: 12031363
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjunctive treatment)
Study: 18584876
Drug: Adjunctive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive treatment with 4 mg triamcinolone acetonide (TA)
Study: 11821454
Drug: Pegfilgrastim (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (100 microg/kg per chemotherapy cycle)
Study: 10518177
Drug: 5-HT antagonist
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT antagonist metergoline
Study: 2202549
Drug: Immediate-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release indomethacin capsules, 75 mg given 3-times daily
Study: 2202550
Drug: Controlled-release indomethacin
Normalized name: indomethacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release indomethacin tablets, 75 mg given at night
Study: 20378563
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg/m²
Study: 20378563
Drug: Prednisolone 60
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg/m²
Study: 18353666
Drug: Dolasetron 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 12.5 mg i.v.
Study: 10987706
Drug: Ampicillin/sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/sulbactam (2 g/1 g) administered intravenously every 6 h
Study: 10987706
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g) administered intravenously every 6 h
Study: 8605592
Drug: Didanosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (400 mg/day) plus Zidovudine (500 mg/day)
Study: 8605592
Drug: Dideoxicytidine (2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideoxicytidine (2.25 mg/day) plus Zidovudine (500 mg/day)
Study: 1396726
Drug: Cotrimoxazole (trimethoprim-sulfamethoxazole)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (trimethoprim-sulfamethoxazole) 40 mg/kg/day
Study: 1396726
Drug: Cotrimoxazole (trimethoprim-sulfamethoxazole)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole (trimethoprim-sulfamethoxazole) 120 mg/kg/day
Study: 3933261
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural morphine (5 mg injected at the end of the operation and subsequently three times a day)
Study: 3933261
Drug: Midthoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midthoracic epidural morphine
Study: 2719236
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural morphine
Study: 22849580
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at 60 mg/m2
Study: 22849580
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at 60 mg/m2 plus bevacizumab at 15 mg/kg
Study: 15911947
Drug: IV diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diltiazem 0.25 mg/kg (maximum 25 mg)
Study: 12888588
Drug: ABLC 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABLC 3 mg/kg/day for 5 days (ABLC-5)
Study: 9482167
Drug: Policosanol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (10 mg/day)
Study: 3282868
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (900 mg daily for 14 days)
Study: 3282868
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg daily)
Study: 24457472
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion of p53 gene (Gendicine, 10vp) combined with hydroxycamptothecin (20 mg), once a week for 3 weeks
Study: 24457472
Drug: Arterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arterial infusion with hydroxycamptothecin (20 mg)
Study: 12683268
Drug: Typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotics
Study: 15203786
Drug: Nicotine skin
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine skin patches (21 mg/24 hr)
Study: 30243424
Drug: Mecamylamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (10 mg/day)
Study: 2929853
Drug: Ivermectin (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (50, 100, 150, or 200 micrograms/kg body wt); 55 recipients of 100 or 200 micrograms/kg doses received a second identical dose the next day
Study: 29550406
Drug: Inactivated whole-cell
Normalized name: cholera, inactivated, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole-cell oral cholera vaccine (OCV)
Study: 28963124
Drug: Placebo (hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (hourly isocaloric maltodextrin drinks)
Study: 21621727
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (no treatment for 6 weeks)
Study: 15192630
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration (Survanta, Ross Laboratories, Columbus, Ohio)
Study: 20472532
Drug: Surfactant administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant administration
Study: 8155034
Drug: Methazolamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methazolamide (50 mg twice daily) for 6 weeks